Polartechnics develops, manufactures and markets revolutionary inventions for the detection of pre-cancer and cancer.

Polartechnics started in 1980's as an Australian based biotechnology company and developed a group of unique patent protected cancer screening devices - TruScreen, SolarScan and MediScan.
These inventions formed a biophysical technology platform using opto-electronic measurements of human tissue interpreted through customised algorithms.

TruScreen and SolarScan are internationally recognised through a number of design and engineering awards, have successfully completed relevant medical trials and gained CE and TGA (Australia) certification.

From 2006 under a new chairman and CEO, Polartechnics has transformed itself into an Australian listed healthcare industry operator specialising in the provision of integrated cancer screening systems.
These cancer screening systems are based on the commercialisation of Polartechnics intellectual property and the TruScreen, SolarScan and MediScan devices.

Polartechnics is focused on screening systems for cervical cancer and related high risk HPV infection, and melanoma, an aggressive deadly skin cancer.

Polartechnics has a global commercialisation strategy for its supply chains and for its sales markets. Polartechnics is involved in product research and development; manufacturing; promotion, education and training; and customer support.

Polartechnics prefers to distribute its products and services through partnerships with nationally based expert medical products distributors. As a consequence, Polartechnics is currently active in Australia and New Zealand; East Asia including China, Korea and Taiwan; South East Asia; South Asia throughout India; Eastern Europe including Greece, Hungary, Turkey; Middle East including Egypt and UAE; and the United Kingdom and Ireland.

To direct its global operations and to readily assess compatible technologies in cancer screening that could be integrated into Polartechnics, the company has established operations centres in Sydney, Australia and New Malden, United Kingdom. Whilst Sydney will act as the hub for our Asian markets, New Malden will allow the extension of Polartechnics operations across Europe, the Middle East, and into Africa and South America.
Our primary aim is to utilise the best medical technology available to provide affordable cancer screening products and services to those markets where early detection of target cancers can lead to significant reductions in existing mortality rates. Further, that the screening systems provided by Polartechnics can be operated by a wide range of health care workers with minimum health system infrastructure investment, and even be initiated by patient self sampling to maximise the screening coverage of the communities to available doctors.

As Polartechnics proves the performance of its cancer screening systems in selected markets, we intend to seek partnering opportunities with relevant benevolent organisations and government agencies to accelerate and extend our operations into the more remote rural areas.
As our company grows, our challenge will be to strike a balance between our commercial objectives to reward our shareholders and our capacity to contribute to healthier communities.